ERBB2 and breast cancer: In patients with HER2+ BC, each 10-U increase of WC was associated with an increased risk of all-cause or BC-specific mortality (HR = 1.36, 95% CI 1.04–2.77; HR = 1.62, 95% CI 1.10–2.37, respectively).